Is Option Care Health, Inc. (OPCH) A Good Stock To Buy Now?

Option Care Health (OPCH) is the largest autarkic supplier of location and alternate-site infusion services successful the United States, operating a high-quality healthcare level anchored successful chronic infusion therapies, immunoglobulin treatments, and anti-infective medications, with beardown payer integration and structurally sticky diligent request driven by the penchant for at-home attraction versus infirmary settings.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The institution has precocious generated quarterly revenues successful the $1.3–1.4 cardinal range, maintains astir 2x nett leverage, and delivers mid-to-high azygous digit EBITDA margins with guardant guidance improving toward ~8.5 percent, reflecting underlying operational stableness contempt near-term volatility. A crisp Q1 2026 gross miss and astir 30 percent stock terms diminution were driven chiefly by Stelara biosimilar disruption wrong chronic inflammatory disease, wherever high-margin infusion volumes were unexpectedly displaced by self-administered alternatives, creating a marketplace cognition of structural request erosion successful a cardinal nett pool.

However, the halfway concern thesis argues this dislocation is mostly cyclical successful the mean term, arsenic meaningful further biosimilar oregon self-administration substitution hazard crossed OPCH's broader molecule portfolio is constricted until precocious 2027 to 2028, with astir therapies exhibiting either dilatory modulation dynamics oregon debased economical impact. The valuation already reflects this pessimism, with OPCH trading astatine a guardant P/E adjacent 11x and EV/EBITDA astir 10x, good beneath healthcare peers and humanities averages, contempt resilient net powerfulness and a ~$1 cardinal buyback programme supporting superior returns.

Additional upside catalysts see insider buying, pipeline enlargement into neurology, oncology, and uncommon illness infusibles, and secular tailwinds from continued migration of treatments from infirmary to location attraction settings.

Overall, the setup is framed arsenic an asymmetric accidental wherever the basal lawsuit implies 10 to 35 percent upside and the bull lawsuit implies 35 to 50 percent upside implicit the adjacent 1 to 3 quarters, portion downside is constricted to astir minus 5 to minus 15 percent, leaving the concern with a skewed risk-reward illustration that remains fundamentally intact adjacent nether cautious marketplace assumptions.